<h1>Amalgamation approval confirms consolidation of multiple pharmaceutical entities into a single surviving animal health company after regulatory review.</h1> The Competition Commission approved the proposed amalgamation of Sequent Research Limited, Viyash Life Sciences and its group companies, Geninn Life Sciences and Vindhya Organics with Sequent Scientific Limited as the ultimate surviving entity. The parties' principal activities are identified (SSL in animal healthcare with APIs, FDFs and analytical services; SRL as a contract research/analytical subsidiary; Viyash group in APIs and FDFs for human healthcare; Geninn as a holding company). The combination is effected through a series of interconnected amalgamation steps and a detailed Commission order will follow.